These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

537 related articles for article (PubMed ID: 31507117)

  • 1. Amyotrophic Lateral Sclerosis: Autoimmune Pathogenic Mechanisms, Clinical Features, and Therapeutic Perspectives.
    Ralli M; Lambiase A; Artico M; de Vincentiis M; Greco A
    Isr Med Assoc J; 2019 Jul; 21(7):438-443. PubMed ID: 31507117
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Riluzole and amyotrophic lateral sclerosis survival: a population-based study in southern Italy.
    Zoccolella S; Beghi E; Palagano G; Fraddosio A; Guerra V; Samarelli V; Lepore V; Simone IL; Lamberti P; Serlenga L; Logroscino G;
    Eur J Neurol; 2007 Mar; 14(3):262-8. PubMed ID: 17355545
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Motor neuron dysfunction in a mouse model of ALS: gender-dependent effect of P2X7 antagonism.
    Cervetto C; Frattaroli D; Maura G; Marcoli M
    Toxicology; 2013 Sep; 311(1-2):69-77. PubMed ID: 23583883
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exploring Multiple Sclerosis (MS) and Amyotrophic Lateral Scler osis (ALS) as Neurodegenerative Diseases and their Treatments: A Review Study.
    Deeb O; Nabulsi M
    Curr Top Med Chem; 2020; 20(26):2391-2403. PubMed ID: 32972341
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epidemiological and clinical features of amyotrophic lateral sclerosis in a Tunisian cohort.
    Kacem I; Sghaier I; Bougatef S; Nasri A; Gargouri A; Ajroud-Driss S; Gouider R
    Amyotroph Lateral Scler Frontotemporal Degener; 2020 Feb; 21(1-2):131-139. PubMed ID: 31858811
    [No Abstract]   [Full Text] [Related]  

  • 6. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND).
    Miller RG; Mitchell JD; Lyon M; Moore DH
    Amyotroph Lateral Scler Other Motor Neuron Disord; 2003 Sep; 4(3):191-206. PubMed ID: 13129806
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanisms for neuronal degeneration in amyotrophic lateral sclerosis and in models of motor neuron death (Review).
    Martin LJ; Price AC; Kaiser A; Shaikh AY; Liu Z
    Int J Mol Med; 2000 Jan; 5(1):3-13. PubMed ID: 10601567
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Riluzole, neuroprotection and amyotrophic lateral sclerosis.
    Cheah BC; Vucic S; Krishnan AV; Kiernan MC
    Curr Med Chem; 2010; 17(18):1942-199. PubMed ID: 20377511
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management and therapeutic perspectives in amyotrophic lateral sclerosis.
    Mathis S; Couratier P; Julian A; Vallat JM; Corcia P; Le Masson G
    Expert Rev Neurother; 2017 Mar; 17(3):263-276. PubMed ID: 27644548
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The endocannabinoid system in amyotrophic lateral sclerosis.
    Bilsland LG; Greensmith L
    Curr Pharm Des; 2008; 14(23):2306-16. PubMed ID: 18781981
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Amyotrophic lateral sclerosis: pathophysiology, diagnosis and management.
    Gordon PH
    CNS Drugs; 2011 Jan; 25(1):1-15. PubMed ID: 21128691
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Estimating Amyotrophic Lateral Sclerosis and Motor Neuron Disease Prevalence in Portugal Using a Pharmaco-Epidemiological Approach and a Bayesian Multiparameter Evidence Synthesis Model.
    Conde B; Winck JC; Azevedo LF
    Neuroepidemiology; 2019; 53(1-2):73-83. PubMed ID: 31117082
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel therapies in development that inhibit motor neuron hyperexcitability in amyotrophic lateral sclerosis.
    Noto Y; Shibuya K; Vucic S; Kiernan MC
    Expert Rev Neurother; 2016 Oct; 16(10):1147-54. PubMed ID: 27314534
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Amyotrophic lateral sclerosis: contemporary concepts in etiopathogenesis and pharmacotherapy.
    Strong MJ
    Expert Opin Investig Drugs; 2004 Dec; 13(12):1593-614. PubMed ID: 15566317
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trends of quality of life changes in amyotrophic lateral sclerosis patients.
    Shamshiri H; Fatehi F; Abolfazli R; Harirchian MH; Sedighi B; Zamani B; Roudbari A; Razazian N; Khamseh F; Nafissi S
    J Neurol Sci; 2016 Sep; 368():35-40. PubMed ID: 27538598
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic news in ALS.
    Corcia P; Beltran S; Bakkouche SE; Couratier P
    Rev Neurol (Paris); 2021 May; 177(5):544-549. PubMed ID: 33781562
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic development in amyotrophic lateral sclerosis.
    Bucchia M; Ramirez A; Parente V; Simone C; Nizzardo M; Magri F; Dametti S; Corti S
    Clin Ther; 2015 Mar; 37(3):668-80. PubMed ID: 25666449
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Provincial Differences in the Diagnosis and Care of Amyotrophic Lateral Sclerosis.
    Hodgkinson VL; Lounsberry J; Mirian A; Genge A; Benstead T; Briemberg H; Grant I; Hader W; Johnston WS; Kalra S; Linassi G; Massie R; Melanson M; O'Connell C; Schellenberg K; Shoesmith C; Taylor S; Worley S; Zinman L; Korngut L
    Can J Neurol Sci; 2018 Nov; 45(6):652-659. PubMed ID: 30430962
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Guanabenz delays the onset of disease symptoms, extends lifespan, improves motor performance and attenuates motor neuron loss in the SOD1 G93A mouse model of amyotrophic lateral sclerosis.
    Jiang HQ; Ren M; Jiang HZ; Wang J; Zhang J; Yin X; Wang SY; Qi Y; Wang XD; Feng HL
    Neuroscience; 2014 Sep; 277():132-8. PubMed ID: 24699224
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current State and Future Directions in the Therapy of ALS.
    Tzeplaeff L; Wilfling S; Requardt MV; Herdick M
    Cells; 2023 May; 12(11):. PubMed ID: 37296644
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.